#ASH22: 'Not so sur­pris­ing': With lack of dura­bil­i­ty, Af­fimed scraps monother­a­py plans in fa­vor of NK cell com­bo

NEW OR­LEANS — Af­fimed won’t move ahead with an ac­cel­er­at­ed ap­proval ap­pli­ca­tion for its drug AFM13, an in­nate cell en­gager it was test­ing in re­lapsed/re­frac­to­ry pe­riph­er­al T-cell lym­phoma, af­ter a lack­lus­ter tri­al re­sult.

The com­pa­ny re­leased toplines from its Phase II tri­al on Sat­ur­day. Pa­tients in the tri­al had a 32.4% ob­jec­tive re­sponse rate to AFM13 as a monother­a­py, but a me­di­an du­ra­tion of re­sponse of on­ly 2.3 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER